Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

222 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Approximately 20% of patients diagnosed with Hodgkin lymphoma will eventually experience progression or relapse after first-line treatment, which carries a significant risk of disease-related death. Although several pilot studies have demonstrated high rates of sustained response with the combination of brentuximab vedotin (BV) and chemotherapy, consistent real-world data are still lacking. Moreover, there is no universally accepted salvage chemotherapy regimen in this setting, and clinical practices vary across centers. This study aims to describe the efficacy and toxicity of the BV + bendamustine (B2) regimen in patients with relapsed/refractory Hodgkin lymphoma (R/R HL) treated in France over a 10-year period, with or without an attempt at consolidative transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.

NCT06295211

Hodgkin Lymphoma

COMPLETED

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

NCT02499627

Lymphatic Diseases

TERMINATED PHASE2

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00831597

Diffuse Large B-Cell Lymphoma

COMPLETED PHASE2

IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

NCT01491841

Non-Hodgkin's Lymphoma

COMPLETED PHASE1

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

NCT02594163

Diffuse Large B-cell Lymphoma Refractory Follicular B-cell Non-Hodgkin's Lymphoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a retrospective observational multicentric study. All patients fulfilling inclusion criteria in participant centers will be included. Clinical data will be obtained from patients medical records.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed or Refractory Hodgkin Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with relapsed or refractory Hodgkin Lymphoma

Brentuximab-Vedotin associated with Bendamustine

Intervention Type DRUG

Patient having received at least one course of the association Brentuximab-Vedotin and Bendamustine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brentuximab-Vedotin associated with Bendamustine

Patient having received at least one course of the association Brentuximab-Vedotin and Bendamustine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with relapsed or refractory HL, after at least one first line of treatment
* Aged 18 years and over
* Having received at least one course of the Brenxutimab-Vedotin J1 and Bendamustine J1 + J2 combination